Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » CDC: At-Risk Flu Patients Should Receive Antivirals

    CDC: At-Risk Flu Patients Should Receive Antivirals

    All hospitalized patients with suspected or confirmed flu

    February 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    CDC: Give Immediate Antivirals to High Risk Patients with Flu Symptoms

    Should Patients at Increased Risk of Bleeding Receive Activated Protein C?

    Related Products

    Should Patients at Increased Risk of Bleeding Receive Activated Protein C? | Single Article

    CDC: Flu vaccine delayed, priority to at-risk patients | Single Article

    Neuraminidase inhibitor (NAI) antiviral medications should be brought to bear early and often to stave off severe and fatal flu infections due to a vaccine mismatch this season, the CDC recommends.1

    “The CDC recommends antiviral medications for treatment of influenza as an important adjunct to annual influenza vaccination,” the agency stated in its health advisory. “Treatment with neuraminidase inhibitors has been shown to have clinical and public health benefit in reducing illness and severe outcomes of influenza based on evidence from randomized controlled trials, meta-analyses of randomized controlled trials, and observational studies during past influenza seasons and during the 2009 H1N1 pandemic.… All hospitalized, severely ill, and high-risk patients with suspected or confirmed influenza should be treated with antivirals.”

    Some of the key CDC recommendations are summarized as follows.

    Any patient with suspected or confirmed influenza in the following categories should be treated as soon as possible with a neuraminidase inhibitor:

    • a patient who has severe, complicated, or progressive illness — this may include outpatients with severe or prolonged progressive symptoms or who develop complications such as pneumonia but are not hospitalized;
    • a patient who is at higher risk for influenza complications but not hospitalized. Patients in this group include children younger than two years;
    • people with chronic pulmonary problems, including asthma; cardiovascular, renal, hepatic, hematological, and metabolic disorders, or neurologic and neurodevelopment conditions such as stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury;
    • people with immunosuppression, including that caused by medications or by HIV infection;
    • women who are pregnant or postpartum (within two weeks after delivery);
    • people aged younger than 19 years who are receiving long-term aspirin therapy;
    • American Indians and Alaska Natives;
    • people with extreme obesity (i.e., body mass index equal to or greater than 40);
    • residents of nursing homes and other chronic care facilities.

    REFERENCE

    1. CDC. Seasonal Influenza A(H3N2) Activity and Antiviral Treatment of Patients with Influenza. Health Alert Network. Dec. 27, 2017. Available at: http://bit.ly/2E9AstE.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 45, No. 2) February 2018
    February 1, 2018

    Table Of Contents

    Severe Flu Season a Call to Action for Infection Preventionists

    CDC: At-Risk Flu Patients Should Receive Antivirals

    Zika Virus: Not Gone, Certainly Not Forgotten

    Changing Human Behavior on Antibiotic Stewardship

    NIH Approves Research to Enhance Pandemic Pathogens

    Pediatricians Call for Mandated Flu Shots for Clinic Staff

    CDC: No Ban on Politically Charged Words

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, Peer Reviewer Patrick Joseph, MD, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing